JP2001523731A - 増殖している細胞を治療するための増殖活性生成物 - Google Patents

増殖している細胞を治療するための増殖活性生成物

Info

Publication number
JP2001523731A
JP2001523731A JP2000521861A JP2000521861A JP2001523731A JP 2001523731 A JP2001523731 A JP 2001523731A JP 2000521861 A JP2000521861 A JP 2000521861A JP 2000521861 A JP2000521861 A JP 2000521861A JP 2001523731 A JP2001523731 A JP 2001523731A
Authority
JP
Japan
Prior art keywords
product
biologically active
cells
product according
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000521861A
Other languages
English (en)
Japanese (ja)
Inventor
フランクス，クリストファー・ラルフ
デラ・ビッタ，ルッジェロ
Original Assignee
バイオイノヴェイション・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオイノヴェイション・リミテッド filed Critical バイオイノヴェイション・リミテッド
Publication of JP2001523731A publication Critical patent/JP2001523731A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2000521861A 1997-11-26 1998-11-25 増殖している細胞を治療するための増殖活性生成物 Pending JP2001523731A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9724838.9 1997-11-26
GBGB9724838.9A GB9724838D0 (en) 1997-11-26 1997-11-26 Compositions
PCT/GB1998/003509 WO1999026660A2 (fr) 1997-11-26 1998-11-25 Produit a activite proliferative utile pour traiter des cellules proliferatives

Publications (1)

Publication Number Publication Date
JP2001523731A true JP2001523731A (ja) 2001-11-27

Family

ID=10822573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000521861A Pending JP2001523731A (ja) 1997-11-26 1998-11-25 増殖している細胞を治療するための増殖活性生成物

Country Status (8)

Country Link
EP (1) EP1032427A2 (fr)
JP (1) JP2001523731A (fr)
AU (1) AU1249999A (fr)
CA (1) CA2311733A1 (fr)
GB (1) GB9724838D0 (fr)
NZ (1) NZ504625A (fr)
WO (1) WO1999026660A2 (fr)
ZA (1) ZA9810759B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5088600A (en) * 1999-06-03 2000-12-28 Bioinnovation Limited Gene therapy products
US7196093B2 (en) 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
KR102220006B1 (ko) 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948B1 (fr) * 1987-12-02 1992-08-19 Neorx Corporation Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle
CA2016584C (fr) * 1989-05-17 1999-06-29 Robert S. Greenfield Conjugats d'anthracycline ayant un nouvel adapteur et methodes de production
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US5248499A (en) * 1991-10-07 1993-09-28 Genentech, Inc. Control of microbial infections in transplant patients
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
GB9724838D0 (en) 1998-01-21
ZA9810759B (en) 2000-05-25
NZ504625A (en) 2002-12-20
CA2311733A1 (fr) 1999-06-03
EP1032427A2 (fr) 2000-09-06
AU1249999A (en) 1999-06-15
WO1999026660A2 (fr) 1999-06-03
WO1999026660A3 (fr) 1999-10-14

Similar Documents

Publication Publication Date Title
US7371371B2 (en) Interleukin-2 mutants with reduced toxicity
US6207802B1 (en) Stem cell factor and compositions
US6248319B1 (en) Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US20030186889A1 (en) Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
KR20010102043A (ko) 항-혈관형성 요법 및 면역요법을 병용한 종양 및 전이의치료 방법
PT95524B (pt) Novos factores poliptidicos com actividade estimuladora de celulas indiferenciadas, processo para a sua preparacao e para a preparacao de composicoes farmaceuticas que os contem
US7144731B2 (en) SCF antibody compositions and methods of using the same
KR20050007359A (ko) 종양 치료를 위한 면역접합체
WO2021018026A1 (fr) Préparation liquide et son application
JP2001523731A (ja) 増殖している細胞を治療するための増殖活性生成物
CA2056555A1 (fr) Agent immunostimulant renfermant de l'interleucine-2 et de la 5'-desoxy-5-fluoro-uridine
US6207454B1 (en) Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
Garnick et al. Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6
US20220001020A1 (en) Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other Agents
EP1185304A2 (fr) Produits de therapie genique
Thomas et al. Biological approaches to cancer therapy
US20020150551A1 (en) Gradual modification, super-agonists and antagonists of signal - proteins and peptides
AU762023B2 (en) Gradual modification, super-agonists and antagonists of signal-proteins and peptides
AU2003248017B2 (en) Gradual modification super-agonists and antagonists of signal-proteins and peptides
Boyano et al. Cyclosporin A Upmodulates the α-Subunit of the Interleukin-2 Receptor and the Metastatic Ability of Murine B16F10 Melanoma Cells
WO1993005801A1 (fr) Utilisation de l'il-5 pour traiter des tumeurs solides
AU2007200889A1 (en) Gradual modification super-agonists and antagonists of signal-proteins and peptides
AU2007201478A1 (en) Stem Cell Factor
WO2010008561A2 (fr) Procédés et compositions de protection contre un traitement cytotoxique